Auditor flags going concern as Armata ends 2025 with $14.1M cash $5.4M lease impairment and a $105.8M non-cash convertible-loan fair-value loss drove the quarter. Debt maturities now run to June 1, 2027.

#ARMP Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata pushes back earnings as FDA backs Phase 3 staph blood infection study AP-SA02 won FDA QIDP status and a Phase 3 trial in staph bacteremia is planned for second-half 2026. Armata also commissioned a 56,000-square-foot plant.

#ARMP Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

www.stocktitan.net/news/ARMP/armata-pharmac...

The Dire MILF (a voluptuous alt blonde with freckles and tattoos) wearing a seafoam satin bra, elf ears, and rose gold glasses. She has one hand behind her head, displaying a luxuriantly hairy armpit

Lonely on the road, bold adventurer?

Hot elven MILFs are standing by for your scry. 🔮

Find me on #NiteFlirt for roleplay that envelops you, authentic kink, + brilliant nerdy companionship

1-800-863-5478 ext: 13922192

#realnsfw #lewdsky #elf #belf #fairysky #fantasy #armp #nsfwfantasy #nsfw ✨

Breaking News: ( NYSE: #ARMP ) /C O R R E C T I O N -- Armata Pharmaceuticals, Inc./

News; ( NYSE: #ARMP ) Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Best Christmas And New Year Sex Toy Sales And Deals | 2025 Find out all you need to know about the Best Christmas And New Year Sex Toy Sales this year this will be a growing post that will grow.

#hairyman #gaydaddy #daddy #hairybody #hairychest #hairymuscle #muscle #gaydad #armp #hairybush #hairycock #uncut #cum #cumshot #cumload #precum #bator #gooner #himbo #chudai #wataa #gay #gayporn #porn #nsfw #nude #beard #gaytop #gaydom #alphaman #hardcock #masturbate

ukdazzz.co.uk/best-christm...

Breaking News: ( NYSE: #ARMP ) Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST Armata Pharmaceuticals (NYSE American: ARMP) will host a KOL webinar on November 25, 2025 at 10:00am EST featuring Dr. Vance G. Fowler Jr. on complicated S. aureus bacteremia and Armata's phage therapy AP-SA02.The company highlighted positive Phase 1b/2a diSArm results presented at IDWeek 2025 showing AP-SA02 plus best available antibiotic therapy produced a higher, earlier cure rate at Test of Cure and a 100% response without relapse at TOC and 28 days later (EOS) versus ~25% lack of response/relapse for placebo plus BAT. AP-SA02 was reported well-tolerated with efficacy against MRSA and MSSA.

#ARMP Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

www.stocktitan.net/news/ARMP/armata-pharmac...

News; ( NYSE: #ARMP ) Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

#ARMP Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

www.stocktitan.net/news/ARMP/armata-pharmac...

News; ( NYSE: #ARMP ) US Companies Moving the Markets, Evening edition <br>Wed, Oct 22, 2025 as of 4:00 pm ET

Breaking News: ( NYSE: #ARMP ) Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025(TM)

First-Ever Structural Analysis: Armata's Therapeutic Phage Pa223 Shows Promise for Antibiotic-Resistant Infections Armata reveals groundbreaking cryo-EM analysis of phage Pa223, a component of AP-PA02 clinical cocktail showing promise in Phase 2 trials for cystic fibrosis and NCFB treatment.

#ARMP Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update Armata Pharmaceuticals (NYSE American: ARMP) announced significant Q2 2025 developments, including a $15 million secured credit agreement with Innoviva and positive topline results from their Phase 1b/2a diSArm trial for AP-SA02, their lead S. aureus therapeutic candidate.The company reported Q2 2025 financial results with grant revenue of $2.2 million, R&D expenses of $6.4 million, and cash position of $4.3 million. Additionally, Armata received $4.65 million in non-dilutive funding from the U.S. Department of Defense.The diSArm trial met all primary endpoints, demonstrating improved clinical outcomes compared to standard antibiotic therapy with no treatment-related serious adverse events. Armata plans to initiate a Phase 3 pivotal trial in 2026 following an FDA end-of-Phase 2 meeting later this year.

#ARMP Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

www.stocktitan.net/news/ARMP/armata-pharmac...

Breaking News: ( NYSE: #ARMP ) Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met. AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy. LOS ANGELES, May 19, 2025/ PRNewswire/-- Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the...

#ARMP Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update Armata Pharmaceuticals (NYSE: ARMP) reported its Q1 2025 financial results and corporate updates. The company anticipates topline results from its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia in H1 2025. Key financial highlights include: revenue of $0.5 million (down from $1.0M in Q1 2024), net loss of $6.5 million ($0.18 per share), and cash position of $11.7 million. The company secured additional funding through a $4.65 million non-dilutive DoD award and a $10 million secured credit agreement with Innoviva. R&D expenses decreased to $5.4 million from $8.0 million year-over-year, while G&A expenses remained relatively stable at $3.3 million.

#ARMP Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata Secures $4.65M DoD Funding: Breakthrough Phase 2 Trial Results Coming for Antibiotic-Resistant Treatment New DoD funding advances novel bacteriophage therapy for drug-resistant infections. Phase 1b/2a trial shows promising signals. See upcoming Q2 data readout details.

#ARMP Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update Armata Pharmaceuticals (NYSE: ARMP) reported Q4 and full-year 2024 results, highlighting significant clinical progress. The company announced positive topline results from its Phase 2 Tailwind study of inhaled AP-PA02 for treating Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis patients, showing statistically significant bacterial reduction.Q4 2024 financial highlights include: Grant revenue of $1.2M (vs $1.5M in Q4 2023)R&D expenses of $8.5M (vs $7.9M in Q4 2023)Net income of $2.6M or $0.07 per basic shareCash position of $14.8M as of December 31, 2024The company secured a $10M secured credit agreement with Innoviva Strategic Opportunities in March 2025. Armata also completed enrollment in its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia, with topline results expected in H1 2025.

#ARMP Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata Lands Critical $10M Funding to Push Revolutionary Phage Therapy Toward FDA Meeting Armata Pharmaceuticals secures strategic financing from Innoviva to advance late-stage bacteremia trials and prepare for crucial FDA discussions on phage therapy candidates.

#ARMP #INVA Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

www.stocktitan.net/news/ARMP/armata-pharmac...

Armata CEO Dr. Deborah Birx Takes Center Stage at Major Bacteriophage Summit Biotechnology leader Armata Pharmaceuticals showcases bacteriophage therapeutics expertise at prestigious summit. Dr. Birx to discuss innovative antibiotic-resistant infection treatments.

#ARMP Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

www.stocktitan.net/news/ARMP/armata-pharmac...

#ARMP Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

www.stocktitan.net/news/ARMP/armata-pharmac...

#ARMP Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

www.stocktitan.net/news/ARMP/armata-pharmac...

JUST IN: ( NYSE: #ARMP ) Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

#StockMarket #News

Breaking News: ( NYSE: #ARMP ) Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

#StockMarket #News